



President's Cancer Panel: A new beginning

2/28/2012

Mission

- **The Panel shall monitor the development and execution of the activities of the National Cancer Program, and shall report directly to the President.**
- **Any delays or blockages in rapid execution of the Program shall immediately be brought to the attention of the President.**

Topics today

- **New appointments to President's Cancer Panel**
- **How we will function**
- **Meeting approach**
- **First topic**
- **Potential topics for other years**
- **Report in process**



Home • Briefing Room • Statements & Releases

Search WhiteHouse.gov Search

The White House

Office of the Press Secretary

For Immediate Release

November 29, 2011

President Obama Announces More Key Administration Posts

WASHINGTON, DC – Today, President Barack Obama announced his intent to nominate the following individuals to key Administration posts:

- **Frederick "Rick" Barton** – Assistant Secretary for Conflict and Stabilization Operations and Coordinator for Reconstruction and Stabilization, Department of State
- **Arun Majumdar** – Under Secretary of Energy, Department of Energy
- **Marie F. Smith** – Member, Social Security Advisory Board

The President also announced his intent to appoint the following individuals to key administration posts:

- **Barbara K. Rimer** – Chairman, President's Cancer Panel
- **Owen N. Witte** – Member, President's Cancer Panel

President Obama said, "These men and women have demonstrated knowledge and dedication throughout their careers. I am grateful they have chosen to take on these important roles, and I look forward to working with them in the months and years to come."

2012 STATE of the UNION



More Information

BLOG POSTS

Michelle Obama: Changing the Conversation on Healthy Eating



In an op-ed published today, the First Lady talks about the progress Let's Move has made in its first two years



Our approach

- **Focus on actionable recommendations**
- **Track recommendations over time**
- **Meeting format based on topic goals**
- **Interaction & discussion among participants**
- **Participants from different sectors and perspectives**

Criteria for topic selection

- **Related to FUNCTIONAL OUTCOMES** that influence resource allocation, organizations, industry practices and, potentially, cancer prevention, detection and therapeutic interventions
- **SIGNIFICANT: AFFECTS CRITICAL ASPECTS** of cancer-related discovery, prevention, early detection, treatment, delivery, control and policy
- **MANAGEABLE AND FOCUSED**
- **CAN LEAD TO ACTIONABLE RECOMMENDATIONS**
- **ADDRESSED** within timeframes and resource constraints of PCP

Criteria for topic selection

- **NOT EXCLUSIVELY FOCUSED ON NCI issues**
- **SALIENT, RELEVANT AND TIMELY**
- **NOT EXAMINED RECENTLY** by other credible leadership organizations (*except where deeper/broader exploration is needed*)
- Based on **SOUND SCIENCE** and policy
- **NOT CREATING GUIDELINES**


2012 Topic

Accelerating Progress in Cancer Prevention: The HPV vaccine example

Rationale

- **Globally, HPV infections cause most cervical cancers: over 560,000 new HPV-related cases/year (cervical and other cancers).**
- **Vaccines protect against most common forms of oncogenic HPV infections (e.g. HPV 16, 18).**
- **Only 1.4% of US males and 32% of US females ages 13-17 have received 3 vaccine doses.**
- **US rates are too low to achieve population potential of HPV vaccines to reduce cancer incidence.**
- **Increasing HPV vaccination could effect a major reduction in HPV-related cancers.**


United States: Incidence and Distribution of Cancers Attributable to HPV



• *Pap screening has reduced the incidence of cervical cancer by ~80%*

Gillison, Chaturvedi, and Lowy. *Cancer* 113: S3036-46, 2008 * From D. Lowy presentation to NCAB, 12/11

Worldwide Incidence and Distribution of Cancers Attributable to HPV*




- *Cervical cancer = ~10% of all female cancers worldwide*
- *~80% of cervical cancers occur in developing world*

Adapted from Parkin, *Int J Cancer* 118:3030, 2006

* From D. Lowy presentation to NCAB, 12/11

Trends in U.S. Vaccination Rates: Ages 13-17 Yrs**

MMWR Vol 60, #33, August 26, 2011



*** Females; adolescent male vaccination 1.4%**

Abbreviations: Tdap = tetanus, diphtheria, acellular pertussis vaccine; MenACWY = meningococcal conjugate vaccine; HPV-1 = human papillomavirus vaccine, ≥ 1 dose; HPV-3 = human papillomavirus, ≥ 3 doses.

* Tdap and MenACWY vaccination recommendations published March and October 2006

† HPV vaccination recommendations published March 2007

** *from presentation at NCI 2011 by Noel Brewer*

2012 Topic

Accelerating Progress in Cancer Prevention: The HPV vaccine example

Approach

- **Workshop model: encourage interaction and discussion**
- **Invite two co-chairs for each of 3 workshops.**
- **Identify provocative questions.**
- **Assess scientific basis for, current status of, and continuing efforts for effective HPV vaccination.**

2012 Topic

Accelerating Progress in Cancer Prevention: The HPV vaccine example

Approach

- **Examine epidemiologic, behavioral, sociopolitical, communication, and policy issues that influence effectiveness of HPV vaccines in reducing population cancer risks.**
- **Also: clinical and economic issues**
- **Consider global impact and strategy.**

2012 Topic

Accelerating Progress in Cancer Prevention: The HPV vaccine example

Workshop goals

- **Develop actionable recommendations that focus on ways to increase uptake of HPV vaccines in US.**
- **Identify lessons learned from vaccination programs that may be applied to future cancer-related vaccines.**
- **Address issues related to global HPV vaccination strategy.**
- **Identify topics and issues that require further study.**

HPV Vaccination as a Model Cancer Prevention Method:

State-of-the-science and evidence

July 24, 2012
San Francisco, CA
(Workshop 1)

- **Preventive vaccine for HPV serotypes most commonly associated with cervical, vulvar, vaginal, anal, penile, oral cavity and oropharyngeal cancers is a major advance in preventive oncology.**
- **Potential impact of HPV vaccine on cancer incidence and mortality has not been realized.**

HPV Vaccination as a Model Cancer Prevention Method:

State-of-the-science and evidence

- **Fundamental science that laid foundation for development of HPV vaccine, specifically, basic, translational, and clinical research that brought the vaccine from discovery to approval**
- **Surveillance and epidemiology to determine:**
 - ✓ **durability of immunity**
 - ✓ **safety**
 - ✓ **cross-protection among multiple oncogenic HPV strains**
 - ✓ **high risk groups**
 - ✓ **incidence of CIN, HPV infections, and cervical, vaginal, vulvar, anal, penile, oral cavity and oropharyngeal cancers among vaccinated populations**

HPV Vaccination as a Model Cancer Prevention Method: State-of-the-science and evidence

- **Implications for future vaccines**
- **Financing development and dissemination of HPV vaccines; implications for other vaccine development**
- **Improvements in formulation and delivery of HPV vaccines that will inform development of future vaccines**

Achieving Widespread HPV Vaccine Dissemination:

**Policy, program, and
communication considerations**

September 13, 2012

Washington, DC

(Workshop 2)

- **US HPV vaccination rates should be increased.**
- **Assess vaccine dissemination, communication/education, sociopolitical issues, barriers to greater use, and current policy environment.**
- **Recommend strategies to improve communication, other critical factors, decision making, and vaccine uptake.**

Achieving Widespread HPV Vaccine Dissemination:

Policy, program, and
communication considerations

- **Policies that determine where and by whom vaccines are administered, and who is eligible to receive them, under what conditions, affect use.**
- **What, if any, policy changes are needed to increase use of HPV vaccines?**
- **Issues related to messaging strategies, campaigns and use of social and other internet media**
- **Vaccine characteristics that are barriers to uptake**
- **Choice of vaccines (Gardasil vs. Cervarix)**

HPV Vaccination :

**Clinical practice issues,
standards and economic implications**

Date & Location TBD

(Workshop 3)

- **Impact of HPV vaccination on cervical cancer rates is uncharacterized.**
- **Cervical cancer screening still is needed to minimize cancer incidence and mortality.**
- **Examine current clinical practice standards for cervical cancer screening—and related economic implications of widespread vaccination.**

HPV Vaccination :

**Clinical practice issues,
standards and economic implications**

- Definition of potential changes in risk evaluation and clinical practice standards that effective HPV vaccination may catalyze**
- Cost-effectiveness of widespread vaccination**
- Economic approaches (e.g., tiered pricing, innovative financing mechanisms, interdisciplinary partnerships) that may increase access to vaccines**
- Potential economic effects of increased vaccination rates on federal, state, and private health care and insurance costs**

Potential future topics

- **Accelerating clinical trials through new discovery pathways and agents, trial designs, statistical methodologies, trial processes and policies**
- **Creating a global network of cancer registries as foundation for global health efforts**
- **Communicating more effectively about cancer—changing the paradigm**

Report in process

The Future of Cancer Research: Accelerating scientific innovation

*Tentatively scheduled for
release late Spring, 2012*